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C holesterol is an essential component of cell membranes, and during the past several years, diabetes researchers have found that membrane cholesterol levels in adipocytes, skeletal muscle fibers and pancreatic beta cells influence insulin action and insulin secretion. Consequently, it is thought that dysregulated cell cholesterol homeostasis could represent a determinant of type 2 diabetes (T2D). Recent 
clinical findings compellingly add to this notion by finding increased T2D susceptibility in individuals with alterations in a variety of cholesterol 
metabolism genes. While it remains imperfectly understood how statins influence glucose metabolism, the fact that they display an influence 
on blood glucose levels and diabetes susceptibility seems to intensify the emerging importance of understanding cellular cholesterol in glucose 
metabolism. Taking this into account, this review first presents cell system and animal model findings that demonstrate the negative impact of 
cellular cholesterol accumulation or diminution on insulin action and insulin secretion. With this framework, a description of how changes in 
cholesterol metabolism genes are associated with T2D susceptibility will be presented. In addition, the connection between statins and T2D risk 
will be reviewed with expanded information on pitavastatin, a newer statin medication that displays actions favoring metabolic health.
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In a series of recent studies, insulin-stimulated glucose disposal in animal 
models and human subjects was found to be inversely related to plasma 
membrane cholesterol content. Aberrantly increased plasma membrane 
cholesterol is seen uniformly in insulin-resistant mice, rats, swine, and 
humans, and normalization restores insulin responsivity.1–4 Mechanistic 
studies in clonal cells, as well as in fat and skeletal muscle tissue 
demonstrate that excess plasma membrane cholesterol reduces cortical 
filamentous actin (F-actin), which is essential for glucose transporter type 
4 (GLUT4) regulation by insulin. In addition to this negative consequence 
of excess plasma membrane cholesterol on insulin action, Llanos et al. 
found the ryanodine receptor calcium signals, which are important for 
GLUT4 regulation, are negatively affected by increased skeletal muscle 
membrane cholesterol.4 Interestingly, exercise known to ward off diabetes 
development has recently been shown to prevent plasma membrane 
cholesterol accumulation, cortical actin filament loss, and insulin resistance 
in mice fed a western-style high-fat diet.5 While F-actin and calcium signaling 
defects that manifest in cholesterol-laden plasma membrane seem to 
represent critical determinates of impaired GLUT4 regulation and glucose 
transport, the precise mechanisms of cellular cholesterol accumulation 
and insulin resistance remain elusive. In fact, Parpal et al. demonstrated 
that progressive cholesterol depletion of 3T3-L1 adipocytes with beta-
cyclodextrin gradually destroyed plasma membrane caveolae structures 
and concomitantly diminished insulin-stimulated glucose transport, in 
effect making cells insulin-resistant.6 The importance of this in metabolic 
health is that upsurges or plunges in plasma membrane cholesterol both 




adversely affect insulin action. Interestingly, a set of pancreatic beta (β)-cell 
studies also demonstrate a strikingly similar damaging impact of too much 
or too little plasma membrane cholesterol on insulin secretion.
In 2007, Brunham et al. studied mice with a specific inactivation of Abca1 
in β cells.7 Abca1 encodes the adenosine 5’-triphosphate (ATP)-binding 
cassette transporter subfamily A member 1 (ABCA1) that mediates the 
rate-limiting step in high-density lipoprotein (HDL) biogenesis by effluxing 
cellular cholesterol to apolipoprotein A1 (ApoA1). Their deletion of β-cell 
ABCA1 increased cholesterol in these cells and impaired insulin secretion, 
suggesting that β-cell cholesterol accumulation may contribute to β-cell 
dysfunction. Subsequent investigation found that islets lacking the related 
cholesterol transporter ABCG1 also had impaired glucose-stimulated 
insulin secretion (GSIS).8 Also, somewhat expectedly, it was found that 
losses of both ABCA1 and ABCG1 induced an exacerbated disturbance in 
β-cell function compared with loss of either transporter alone.9 Another 
line of investigation revealed elevated islet cholesterol levels and impaired 
GSIS in ApoE-deficient mice.10 Further experimental manipulation of β-cell 
cholesterol levels in this study demonstrated that excess membrane 
cholesterol impairs GSIS, whereas cholesterol normalization enhances 
GSIS.10 Interestingly, in the context of what is seen in adipose tissue and 
skeletal muscle cells, it was also found that cholesterol-overloaded 
β cells exhibit diminished glucose-induced actin reorganization, membrane 
depolarization, and insulin secretion.11 In terms of human β-cell health, 
infusion of reconstituted HDL in patients with T2D improves β-cell function, 
whereas carriers of loss-of-function mutations in ABCA1 have impaired 
β-cell function.12 Of note, like extreme plunges in plasma membrane 
cholesterol negatively impacting insulin action, Tsuchiya et al. found that 
cholesterol composition of insulin secretory granule (SG) membrane is 
crucial for GSIS and SG formation.13
Together, these studies support the case that changes in cellular cholesterol 
metabolism may represent an etiological factor of T2D development. Next, 
we summarize genetic studies that come to the same conclusion. Also, 
new data suggesting how caloric excess may fuel cholesterol accumulation 
are highlighted. Finally, we present data and perspective on how statins 
may mechanistically influence glucose metabolism.
Cholesterol genes and diabetes
Several human genetic studies suggest a relationship between increased 
cellular cholesterol levels and alterations in glycemia. Ding et al. quantified 
the transcriptome and epigenome in monocytes from 1,264 participants 
in the Multi-Ethnic Study of Atherosclerosis, and found that alterations in 
a network of coexpressed cholesterol metabolism genes were associated 
with T2D.14 This network included 11 genes related to sterol influx (↑LDLR, 
↓MYLIP), synthesis (↑SCD, FADS1, HMGCS1, FDFT1, SQLE, CYP51A1, 
SC4MOL), and efflux (↓ABCA1, ABCG1), producing a molecular profile 
expected to increase intracellular cholesterol. Recent examination of multi-
tissue transcriptomes and epigenomes suggest that these cholesterol 
metabolism genes are similarly altered in human adipose tissue.15,16 
Moreover, obesity-driven modifications in the epigenome predicted T2D, 
independent of conventional risk factors such as body mass index (BMI) 
and glycemia.16 Many of the methylation sites responsive to obesity were 
involved in lipid and lipoprotein metabolism. Identified in this analysis was 
a strong relationship between the methylation of ABCG1 and T2D.16 As 
expanded on below, genetic mutations resulting in diminished circulatory 
levels of both low-density and high-density lipoproteins are significantly 
associated with T2D.17 Of interest is that these changes could have 
significant bearing on cellular cholesterol levels and thus possibly explain 
the increased T2D risk.
Low-density lipoprotein metabolism and 
type 2 diabetes
Low-density lipoprotein (LDL) receptors (LDLRs) mediate the cellular 
uptake of LDL-cholesterol (LDL-C) from the circulation. Myosin regulatory 
light chain-interacting protein (MYLIP) promotes LDLR degradation. Thus, 
increased LDLR gene expression and/or decreased MYLIP gene expression 
would favor diabetogenic LDLR-mediated cholesterol delivery to adipocytes, 
pancreatic β-cells, and skeletal muscle fibers. Consistent with this removal 
of LDL-C from the blood, lower circulating LDL-C levels have recently been 
found to be significantly associated with T2D susceptibility.17 Interestingly, 
unlike ubiquitous MYLIP tissue expression, proprotein convertase subtilisin/
kexin type 9 (PCSK9), which also promotes LDLR degradation, is produced 
predominantly in the liver. Therefore, PCSK9 inhibitors, unlike the genetic 
loss of MYLIP, would not be expected to increase cholesterol levels in non-
hepatic cells. Whether PCSK9 inhibitors, however, increase T2D risk is not 
yet fully known.18 Contrariwise to increased LDLRs and decreased LDL-C 
associating with T2D, loss-of-function mutations in the LDLR, as seen in 
familial hypercholesterolemia (FH), protects individuals from T2D risk.19 
In fact, the odds of developing T2D decreased linearly as the severity of 
FH increased,19 or, from another prospective, as cellular ability to uptake 
cholesterol decreased.
High-density lipoprotein metabolism and 
type 2 diabetes
A significant association between genetically determined lower HDL-C 
and T2D has also been found.17 Unlike the LDLs that deliver cholesterol to 
cells, HDLs remove cholesterol from cells. Many steps are involved in HDL 
metabolism and deserve an overview for discussion on HDL metabolism 
changes as a possible contributor to T2D. Briefly, HDLs originate from the 
liver, intestine, chylomicron (CM), and very-low-density lipoprotein (VLDL). 
The liver secretes lipid-poor ApoA1 called nascent or precursor HDL, 
the intestine directly synthesizes these particles, and lipoprotein lipase 
(LPL)-mediated lipolysis of CMs and VLDLs releases surface ApoA1 and 
phospholipids that also generate nascent HDLs. This later CM and VLDL-
generated ApoA1 production is facilitated by phospholipid transfer protein 
(PLTP). These liver-, intestine-, CM-, and VLDL-derived nascent HDLs 
accept free cholesterol from cell membranes with excess cholesterol. 
This transfer of free cholesterol to HDLs is mediated by ABCA1, the class 
B, type 1 scavenger receptor (SR-B1), as well as other cell surface proteins 
(e.g., ABCG1). Following the transfer of free cholesterol to the surface of 
the nascent HDLs, the free cholesterol is esterified by lecithin: cholesterol 
acyltransferase (LCAT) and the formed cholesterol esters move away 
from the surface to a cholesterol ester-rich core forming a small, 
spherical, mature HDL particle (designated HDL3). Through this same 
LCAT-mediated process HDL3 accepts cellular free cholesterol, grows in 
size, and matures to a form designated as HDL2. Cholesterol ester transfer 
protein (CETP) facilitates the transfer of cholesterol esters from HDL2 to 
the lower density lipoproteins (VLDL, IDL, LDL) that transit to the liver for 
excretion. As the HDL2 particles becomes devoid of cholesterol esters, 
hepatic lipase hydrolyzes triglycerides and phospholipids that the HDL2 
molecule accumulated and this reconverts HDL2 to HDL3. The regenerated 
HDL3 cycles back through this pathway of accepting free cholesterol and 
transitioning to HDL2 and then back to HDL3.
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Genetic mutations in several of the above mentioned HDL-regulatory 
system components tend to increase a carrier’s risk for T2D. 
For example, Lara-Riegos et al. found T2D susceptibility in Mexican 
Mestizos was associated with a loss-of-function mutation in ABCA1;20 
however, genetic variation in ABCA1 was not found to predict T2D in 
other populations.21 Moreover, mutation in genes for ApoA1, CETP, 
SR-B1, and Niemann-Pick disease, type C1 (NPC1) tend to increase a 
carrier’s risk for T2D.22–26 Loss-of-function mutations in ApoA1, CETP, 
and SR-B1 would negatively impact HDL functionality in accepting 
free cholesterol from cells with excess cholesterol. Efflux mutations 
in chromosome 9q31 in people with Tangier disease lead to defective 
ABCA1 transporters and many of these patients manifest impairments 
in insulin action and insulin secretion.27 Similarly, a loss-of-function 
mutation in NPC1, a gene mutated in Niemann-Pick disease that 
disrupts intracellular cholesterol transport and accumulation in late 
endosomes and lysosomes, indirectly impedes ABCA1-mediated 
cholesterol efflux by sequestering this cholesterol transporter in the 
endosomal compartment.28 A similar trapping of ABCA1 has been 
reported in insulin-resistant 3T3-L1 adipocytes with a cholesterol-laden 
plasma membrane where it was also found that endosomal membrane 
cholesterol was increased with ABCA1, away from its functional site of 
free cholesterol transfer to ApoA1.29
HMG-CoA reductase regulation and T2D
While genetic-related decelerations in HDL-mediated cellular cholesterol 
efflux and/or accelerations in LDL-mediated delivery as a basis of 
T2D warrants further investigation, emerging evidence also suggests 
diabetogenic increases in cellular cholesterol may arise from caloric 
excess associated increases in cholesterol biosynthesis. For example, 
a series of recent in vitro studies have found that excess glucose flux 
through the hexosamine biosynthesis pathway (HBP), a pathway known 
to impair insulin action in animals and humans, increases cellular 
membrane cholesterol. Mechanistically, HBP-mediated increases in 
O-linked N-acetylglucosamine modification of the transcription factor Sp1 
triggers the transcriptional activation of HMG-CoA reductase (HMGR), the 
rate-limiting enzyme in cholesterol biosynthesis.1,3,29,30 This HBP-induced 
cholesterolgenic transcriptional response increases plasma membrane 
cholesterol reducing cortical F-actin and insulin-stimulated GLUT4-
mediated glucose transport, as well as increases endosomal membrane 
cholesterol that sequesters ABCA1 and thus, suppresses cholesterol 
efflux capacity of the insulin resistant cells.1,3,29,30 Strikingly, inhibition 
of the HBP, or Sp1 binding to DNA, blocked membrane cholesterol 
accumulation, F-actin loss, and the dysregulation in both GLUT4-mediated 
glucose transport and ABCA1/ApoA1-mediated cholesterol efflux.1,3,29,30 
Although it is not known whether excess cholesterol content measured 
in insulin-resistant animal and human muscles results from increased 
HBP activity, this pathway is documented to cause insulin resistance in 
animal models and human subjects, and is increased in skeletal muscle 
of patients with T2D.31 Considering that an increase in HBP activity, which 
normally accounts for 2% of total glucose flux, to 4–6% impairs insulin 
action, aberrant cholesterol biosynthesis could represent an imperfectly 
understood mechanism of HBP-mediated insulin resistance.32 Also, 
considering that at the level of the pancreatic β-cell, there is evidence 
that hyperglycemia itself can lead to many of the defects in insulin 
secretion that are observed in T2D,32 future studies of the role of this 
pathway in cholesterol accumulation/toxicity in adipocytes, pancreatic 
β cells, and skeletal muscle in vivo are clearly indicated.
Challenges, opportunities, and lessons from 
statin therapy
Despite the unequivocal importance of cholesterol-lowering therapy in 
preventing cardiovascular disease, there is a modest risk of T2D with statin 
therapy. With this risk, a significant challenge and value exist in untangling 
the relationship between statins and glucose metabolism. Interestingly, 
in the context of this review, nearly two decades of randomized control 
trials and meta-analyses suggest that the risk of T2D is not the same 
among statins. Furthermore, recent network meta-analyses,33 as well as 
a Delphi study that ascertained the opinion of primary care physicians 
and specialists with experience in treating dyslipidemia,34 have ranked 
different statins in order of diabetogenicity, with atorvastatin, simvastatin, 
and rosuvastatin being the most diabetogenic; lovastatin and fluvastatin 
having an intermediate risk; and pravastatin and pitavastatin having the 
lowest diabetogenicity. In fact, basic and clinical data suggest that these 
least diabetogenic statins, especially pitavastatin, may even exhibit a 
positive effect on glucose metabolism.35–43 Intricately layered with our full 
understanding of why and how statins negatively or positively impact 
glycemic health is an array of factors including patient characteristics and 
integrative control mechanisms of cholesterol regulation. It is also now 
recognized that high-potency, high-dose, and long-treatment durations 
add to the diabetogenicity of statins, however, pitavastatin, a fully synthetic 
and high-potency statin,44 is a notable exception that displays many 
cellular cholesterol homeostatic antidiabetic attributes, which will be 
reviewed below.
It is first important to note, however, that the diabetogenicity associated 
with statins as a class corresponds with studies that have found loss-of-
function mutations in the HMGR gene to increase T2D risk.45 Cholesterol 
biosynthesis pathway intermediates, reduced with HMGR inhibition, 
are essential for signaling and transport processes that mediate insulin-
stimulated GLUT4 translocation and glucose-stimulated insulin secretory 
granule trafficking. Brault et al. has recently reviewed studies demonstrating 
the impact statins have on pathways mediated by intermediates of the 
cholesterol synthesis pathway.46 This discussion focuses on the potential 
of statins to directly impact the delicate balance of cellular cholesterol. 
For example, studies introduced earlier by Parpal et al. and Tsuchiya et al. 
document the necessity of cellular cholesterol for insulin signaling and 
insulin secretory granule formation.6,13 Reduced cholesterol synthesis could 
decrease cellular cholesterol causing cells to respond in a similar manner.
Intuitively, we would expect reduced membrane cholesterol to result from 
HMGR inhibition by statins. However, there is little in vivo documentation of 
statin effects on membrane cholesterol content. It is also noteworthy that 
inhibition of cholesterol biosynthesis causes a cascade of compensatory 
responses intended to maintain a functional level of membrane cholesterol 
and cholesterol biosynthetic intermediates. There is a possibility that 
compensation increases cellular cholesterol by turning up cholesterol 
influx and decreasing efflux. For example, like the upregulation of LDLRs 
that occurs in the liver with HMGR inhibition by statins, muscle LDLRs and 
LDL-C uptake are increased in mice treated with high doses of simvastatin.47 
It has also been found that skeletal muscle LDL-C uptake is increased in 
statin-treated mice overexpressing LPL in skeletal muscle.47 These data 
suggest that LPL (the primary enzyme for intravascular hydrolysis of 
triglyceride [TG]), could also be an important mediator of skeletal muscle 
cholesterol uptake by increasing the availability of LDLC from VLDL/IDL 
conversion. Notably, statins increase LPL serum mass and activity in T2D.48–50 
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Perhaps these findings offer an alternative explanation as to why statins 
increase, albeit modestly, the risk of T2D.33,51–55 Interestingly, LPL activity was 
not increased in guinea pigs treated with pitavastatin,56 consistent with its 
neutral effect on blood glucose or T2D risk, however, increased mRNA/
protein expression levels of LPL have been reported in 3T3-L1 adipocytes 
and L6 myotubes treated with pitavastatin, suggesting that this statin may 
have this capacity.48,57
Another facet of HMGR inhibition is cellular compensatory mechanisms 
which appear to be mediated by increased transcription of SREBPs and 
two associated microRNAs (miR), miR-33a and miR-33b.58,59 In response to 
statins, SREBPs and miR-33a/b increase HMGR and LDLR, and decrease 
ABCA1, ABCG1, NPC1, and AMPK.58,59 These metabolic changes are 
advantageous for reducing circulating blood cholesterol, although an 
exaggerated response in adipocytes, pancreatic β-cells, or skeletal muscle 
fibers could have deleterious consequences on glucose regulation. While 
these possible adverse side-effects of HMGR inhibition could explain the 
greater diabetogenicity of atorvastatin, simvastatin, and rosuvastatin 
that generally promote, especially at high-doses, an increased risk of 
T2D development,53,55,60 these statins have also been shown to improve 
insulin sensitivity in some populations with diabetes.61–69 Similarly, although 
the preponderance of studies with pravastatin suggest that this statin 
reduces T2D risk, a significant relative increase in diabetes incidence has 
been observed in elderly patients.70 Two recent meta-analyses of large 
randomized, controlled trials found that either being older (average age >60 
years) or being treated with intensive-dose statin therapy leads to a higher 
incidence of new-onset diabetes.53,55
A start to understanding how statins could have beneficial, neutral, or 
adverse effects on glucose metabolism could be a close examination 
of pitavastatin’s qualities which make this statin neutral to, or protective 
of, glucose disturbances, and T2D. Pitavastatin was demonstrated to 
have neutral effects on glucose homeostasis in patients with metabolic 
syndrome in the CAPTAIN and PREVAIL US trials, independent of its efficacy 
in reducing atherogenic lipoprotein levels.71 In a comparison of pitavastatin 
and atorvastatin in Japanese patients with hypercholesterolemia (the 
CHIBA study; NCT02193698), waist circumference, body weight, and 
body mass index were all significantly correlated with percent reduction 
of non-HDL-C in the atorvastatin group, whereas pitavastatin showed 
consistent reduction of non-HDL-C, regardless of body size.72 In addition, in 
a prospective randomized controlled trial of 1,260 patients with impaired 
glucose tolerance, the J-PREDICT study (NCT00301392), pitavastatin was 
shown to have a neutral effect and possibly even a protective effect against 
the development of diabetes.73 Meta-analysis of the largest contemporary 
dataset involving 4,815 participants that assessed the impact of pitavastatin 
on glycemia and the risk of diabetes found that pitavastatin did not 
adversely affect glucose metabolism or the development of diabetes in 
comparison with placebo.74 This was also determined in a recent network 
analysis that found pitavastatin to be the least diabetogenic. This analysis 
included 29 trials in which 163,039 participants had been randomized; 
among these, 141,863 were non-diabetic patients. While statins, as a 
class, significantly increased the likelihood of developing diabetes by 12% 
(pooled odds ratio [OR] 1.12, 95% confidence interval [CI] 1.05–1.21, I2 36%, 
p=0.002), the OR of pitavastatin was the lowest (OR 0.74, 95% CI 0.31–1.77); 
whereas the highest risk was associated with atorvastatin 80 mg (OR 1.34, 
95%CI 1.14–1.57). Several other trials also support limited, if any, adverse 
effects of pitavastatin in patients with metabolic syndrome (CHIBA72 and 
CAPTAIN/PREVAIL-US trials;71 NCT01256476), or in those with impaired 
glucose tolerance (J-PREDICT; NCT00301392).73
Unlike other statin drugs, pitavastatin has been demonstrated to 
consistently produce significantly greater HDL-C elevations that are 
maintained, or increased, over time.41,74–77 This action may counterbalance 
any unwanted upregulation of LDLRs in skeletal muscle by augmenting 
ABCA1/ApoA1-mediated cholesterol efflux. This key process in restoring 
cellular cholesterol balance may also be enhanced by increased ApoA1 
generation. Maejima et al. found that pitavastatin efficiently increases 
ApoA1 in culture medium of HepG2 cells by promoting ApoA1 production 
through inhibition of HMGR, suppression of Rho activity, and by protecting 
ApoA1 from catabolism through ABCA1 induction and lipidation of ApoA1.78 
Interestingly, endothelial lipase (EL), a relatively recent addition to the 
triglyceride lipase gene family, is a major determinant of HDL-C metabolism. 
This lipase participates in HDL-C metabolism by promoting the turnover of 
HDL-C components and increasing the catabolism of ApoA1. A recent study 
by Kojima et al. found that pitavastatin suppressed basal and stimulated EL 
expression in cultured endothelial cells and mouse tissues.79 Furthermore, 
in that study plasma EL concentrations in human subjects were found 
to be negatively associated with plasma HDL-C levels in patients with 
cardiovascular diseases, and pitavastatin treatment reduced plasma EL 
levels and increased HDL-C levels in patients with hypercholesterolaemia.79 
Whether other statins have this capacity to concomitantly increase key 
components of the reverse cholesterol transport pathway to ameliorate 
cellular cholesterol toxicity is unknown, yet perhaps this explains the 
unique relationship between pitavastatin and glucose.
Pitavastatin also has several other pharmacological features that translate 
into a broad range of anti-diabetic actions. For example, altered adipokine 
levels (↓adiponectin, ↑resistin) and inflammatory factors (↑TNFα, ↑IL-6), 
as well as oxidative stress, mitochondrial dysfunction and ER stress are 
implicated in obesity-associated insulin resistance via their disruptive 
actions on insulin signaling.80 Note that the loss of insulin signaling 
induced by these obesity-associated changes may manifest later in T2D 
development, as an emerging view is that the onset of insulin resistance is 
not associated with defective insulin signaling.3,81,82 Regardless, pitavastatin 
administration has been found to significantly decrease human serum 
resistin levels.83 This effect of lowering resistin was also measured in a 
human breast cancer cell line.84 In that study, pitavastatin inhibited the 
proliferation and suppressed the nuclear expression of NF-κB p65 induced 
by TNF-α, an inflammatory pathway that contributes to insulin resistance.80 
Several clinical studies have also found that pitavastatin possesses an 
adiponectin-increasing effect in hyperlipidemic patients with and without 
T2D.85–90 Adiponectin is a protein with antiatherosclerotic, anti-inflammatory, 
and antidiabetogenic properties exerted on liver, skeletal muscle, adipose 
tissue and pancreatic β-cells.90 Mechanistically, adiponectin stimulates 
AMPK, a kinase that suppresses energy-consuming pathways such as 
hexosamine and cholesterol biosynthesis.91–93 We have found that AMPK 
stimulation improves GLUT4-mediated glucose transport and ABCA1/
ApoA1-mediated cholesterol efflux from insulin-resistant 3T3-L1 adipocytes 
via lowering membrane cholesterol levels.2,29,94
Future directions
The studies cited point to crucially important aspects of cellular 
cholesterol regulation on blood glucose control. Mechanistically, cell 
data suggest that the HBP may funnel excess glucose into cholesterol 
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biosynthesis, however, whether this occurs in vivo is not known. An 
interesting perspective regarding this occurring in adipose tissue is that 
membrane cholesterol accumulation would permit cell enlargement and, 
over time, perhaps hypertrophic obesity. Interestingly, this cholesterol-
laden membrane would also have defects in insulin-regulation of glucose 
transport, yet perhaps not in lipid storage. At the same time, this HBP-
mediated transcriptional cholesterolgenic response in skeletal muscle 
also impairs glucose transport regulation by insulin and in a tissue 
responsible for the majority of blood glucose disposal. Whether an 
early aspect of pancreatic β-cell failure also results from HBP-mediated 
cholesterol biosynthesis/accumulation is not known. An interesting 
possibility is that obesity, insulin resistance, and pancreatic β-cell failure 
arise simultaneously from a defect in cholesterol regulation. This scenario 
could explain how body mass appears to impact statin diabetogenicity. 
For example, an observation made in the Women’s Health Initiative (WHI) 
study was that there was a greater risk for statin-induced new-onset 
diabetes in females with a BMI lower than 25.0 kg/m2 compared with 
those with a BMI of 30.0 kg/m2 or higher.95 Although the WHI study was 
an observational study, it suggests, somewhat counterintuitively, that a 
leaner phenotype may be associated with a greater risk, and this may 
be relevant in the context of the HBP/cholesterol response model. For 
instance, given that a patient’s BMI likely reflects his/her eating/lifestyle 
habits, a BMI lower than 25.0 kg/m2 would likely be associated with 
normal cellular HBP activity and a cellular cholesterol status that may be 
vulnerable to statin therapy for reasons already detailed. Similarly, Daido 
et al. found that pitavastatin administration decreased fasting blood 
glucose levels in a subgroup of Japanese patients with a BMI of 25 kg/m2 or 
higher.41 This factor was not found to differ before and after administration 
of pitavastatin in overall analysis of all the subjects. Therefore, a precise 
cellular and molecular understanding of cholesterol-glucose interactions 
as they relate to metabolic health needs to be evaluated in the setting 
of a range of BMIs. Moreover, a clinical consideration is that lifestyle and 
many pharmacological interventions apparently mediate improvement in 
glucose regulation via increasing AMPK activity.
Conclusions
Mechanistically, research summarized in this review suggests that caloric 
excess modifies nutrient sensing pathways to favor cellular cholesterol 
accumulation. The accumulation of cellular cholesterol in turn alters 
muscle, adipose, and β-cell homeostasis, promoting insulin resistance 
and pancreatic β-cell failure. The human genetics studies cited clearly 
demonstrate that obesity drives epigenome and transcriptome changes 
in cholesterol metabolism, which significantly predispose people to T2D. 
Statins as a class, like caloric excess, modify cholesterol pathways in a 
manner that has the potential to drive cellular cholesterol accumulation. 
On the other hand, pitavastatin seems unique in this regard as it favorably 
engages pathways that not only lower blood cholesterol, but also excess 
cellular cholesterol. 
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